@Article{096504016X14586627440156,
AUTHOR = {Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal, Michael Boyiadzis},
TITLE = {Mitoxantrone and Etoposide for the Treatment of Acute Myeloid  Leukemia Patients in First Relapse},
JOURNAL = {Oncology Research},
VOLUME = {24},
YEAR = {2016},
NUMBER = {2},
PAGES = {73--80},
URL = {http://www.techscience.com/or/v24n2/56952},
ISSN = {1555-3906},
ABSTRACT = {Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no 
standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement 
of CR in 91 AML patients in first relapse who were treated with the mitoxantrone–etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR 
included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median overall 
survival for all patients was 7.4 months. The survival of patients who achieved CR and underwent allogeneic 
hematopoietic cell transplantation (allo-HCT) was higher than those who achieved CR and did not undergo 
allo-HCT (35.3 months vs. 16.8 months, <i>p</i>=0.057). The median duration of relapse-free survival was 12.7 
months in the patients achieving CR. Older age at the time of AML relapse was associated with worse overall 
survival. The all-cause 4-week mortality rate was 4%, and the all-cause 8-week mortality rate was 13%. The 
findings of this study underscore the need for newer therapies, especially those that will improve the ability for 
patients with relapsed AML to achieve CR and to allow them to receive additional therapies.},
DOI = {10.3727/096504016X14586627440156}
}